Lineage Cell Therapeutics (LCTX) Accounts Payables (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Accounts Payables of $5.6 million for Q1 2026, up 179.05% year-over-year from $2.0 million in Q1 2025, and up 137.8% quarter-over-quarter from $2.3 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Accounts Payables (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Accounts Payables history runs 17 years deep, the most recent figure standing at $5.6 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 179.05% year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $5.6 million (up 179.05% YoY), while the FY2025 annual figure was $2.3 million, down 56.94% from the prior year.
- Accounts Payables for Q1 2026 stood at $5.6 million, up from $2.3 million in the prior quarter.
- The five-year high for Accounts Payables was $9.8 million in Q3 2022, with the low at $1.5 million in Q2 2025.
- The 5-year median for Accounts Payables is $5.3 million (2023), against an average of $5.4 million.
- The sharpest annual moves came in 2022 and 2025: Accounts Payables soared 220.24% in 2022, then sank 70.17% in 2025.
- Lineage Cell Therapeutics' Accounts Payables stood at $8.6 million in 2022, then declined by 27.16% to $6.3 million in 2023, then retreated by 13.29% to $5.4 million in 2024, then plunged by 56.94% to $2.3 million in 2025, then surged by 137.8% to $5.6 million in 2026.
- Business Quant data shows LCTX's Accounts Payables at $5.6 million in Q1 2026, $2.3 million in Q4 2025, and $4.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 5.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.39 Mn |
| Mar 31, 2026 | 5.57 Mn |
| Dec 31, 2025 | 2.34 Mn |
| Sep 30, 2025 | 4.55 Mn |
| Jun 30, 2025 | 1.50 Mn |
| Mar 31, 2025 | 2.00 Mn |
| Dec 31, 2024 | 5.44 Mn |
| Sep 30, 2024 | 1.60 Mn |
| Jun 30, 2024 | 5.02 Mn |
| Mar 31, 2024 | 5.68 Mn |
| Dec 31, 2023 | 6.27 Mn |
| Sep 30, 2023 | 5.03 Mn |
| Jun 30, 2023 | 4.69 Mn |
| Mar 31, 2023 | 5.25 Mn |
| Dec 31, 2022 | 8.61 Mn |
| Sep 30, 2022 | 9.81 Mn |
| Jun 30, 2022 | 8.68 Mn |
| Mar 31, 2022 | 8.96 Mn |
| Dec 31, 2021 | 27.97 Mn |
| Sep 30, 2021 | 3.46 Mn |